President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones, including FDA breakthrough Device Designation, and what Imagion Biosystems expects to achieve in 2020.
Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update
July 15, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging